Premium Nahrungsergänzungsmittel | artgerecht

CEA Tumor Marker – Levels, Meaning & Clinical Use

The CEA tumor marker is a protein found in the blood that may be elevated in certain cancers. It is used to monitor disease progression and treatment response.

Regular tips about health Regular tips about health

Things worth knowing about "CEA tumor marker"

The CEA tumor marker is a protein found in the blood that may be elevated in certain cancers. It is used to monitor disease progression and treatment response.

What is the CEA Tumor Marker?

CEA stands for Carcinoembryonic Antigen. It is a glycoprotein – a protein with sugar components – that is naturally produced during embryonic development. In healthy adults, CEA is present only in very small amounts in the blood. Elevated CEA levels may indicate certain cancers or, in some cases, benign (non-cancerous) conditions.

What is the CEA Tumor Marker Used For?

The CEA blood test is primarily used in the following clinical situations:

Monitoring cancer progression: CEA is especially useful for tracking the effectiveness of treatment and detecting recurrences (relapses), particularly in colorectal cancer (colon cancer).
Treatment monitoring: During chemotherapy or after surgery, CEA levels can indicate whether the treatment is working.
Prognosis assessment: A markedly elevated CEA level before surgery may suggest an advanced stage of cancer.

Important: CEA is not a suitable screening test for early cancer detection in healthy individuals, as levels can also rise in benign conditions and the test is not specific enough for a reliable standalone diagnosis.

Which Conditions Can Cause Elevated CEA Levels?

Malignant Conditions (Cancer)

Colorectal cancer (colon cancer) – most common indication
Stomach cancer (gastric carcinoma)
Pancreatic cancer
Lung cancer
Breast cancer
Thyroid cancer (medullary thyroid carcinoma)
Liver cancer and liver metastases

Benign (Non-Cancerous) Conditions

Inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis)
Liver cirrhosis and other liver diseases
Lung conditions (e.g., pneumonia, COPD)
Pancreatitis (inflammation of the pancreas)
Smoking (tobacco use can elevate CEA levels)

Normal Values and Interpretation

The normal CEA level in non-smokers is generally below 3.0 – 5.0 ng/mL (nanograms per milliliter). In smokers, levels may be slightly higher (up to approximately 5.0 – 10.0 ng/mL). Reference ranges may vary slightly between laboratories.

Mildly elevated values: Often associated with benign conditions or smoking.
Markedly elevated values (above 10 ng/mL): More suggestive of a malignant condition, but must always be interpreted within the overall clinical context.
Decreasing values during therapy: A positive sign indicating a response to treatment.
Rising values after therapy: May indicate a recurrence (relapse) of the cancer.

How is CEA Measured?

The CEA level is determined from a simple blood sample (venous blood draw). The sample is analyzed in a laboratory using immunological methods such as ELISA or chemiluminescence immunoassay. No special preparation is generally required, although smoking should ideally be avoided before the blood draw, as it can temporarily raise CEA levels.

Limitations of the CEA Tumor Marker

CEA is neither sufficiently sensitive nor specific enough to be used alone for diagnosing cancer. This means:

Not all cancer patients have elevated CEA levels (false-negative results are possible).
Elevated CEA levels can occur without cancer being present (false-positive results are possible).

Therefore, CEA is always evaluated in combination with other diagnostic tools such as imaging studies, biopsy, and additional tumor markers.

References

Duffy MJ. - Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? - Clinical Chemistry, 2001; 47(4): 624–630. PubMed PMID: 11274010.
Sturgeon CM et al. - National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers - Clinical Chemistry, 2008; 54(12): e11–e79.
Locker GY et al. - ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer - Journal of Clinical Oncology, 2006; 24(33): 5313–5327.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.